Cargando…

Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece

OBJECTIVE: The objectives of this study were to elicit self-reported health status, quantify osteoporosis-related burden, and understand preferences for treatment attributes among postmenopausal women with severe osteoporosis in Greece. METHODS: Postmenopausal women with self-reported severe osteopo...

Descripción completa

Detalles Bibliográficos
Autores principales: Souliotis, Kyriakos, Golna, Christina, Poimenidou, Christina, Drakopoulou, Tatiana, Tsekoura, Memi, Willems, Damon, Kountouris, Vasileios, Makras, Polyzois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840367/
https://www.ncbi.nlm.nih.gov/pubmed/36647442
http://dx.doi.org/10.2147/PPA.S385351
_version_ 1784869626926071808
author Souliotis, Kyriakos
Golna, Christina
Poimenidou, Christina
Drakopoulou, Tatiana
Tsekoura, Memi
Willems, Damon
Kountouris, Vasileios
Makras, Polyzois
author_facet Souliotis, Kyriakos
Golna, Christina
Poimenidou, Christina
Drakopoulou, Tatiana
Tsekoura, Memi
Willems, Damon
Kountouris, Vasileios
Makras, Polyzois
author_sort Souliotis, Kyriakos
collection PubMed
description OBJECTIVE: The objectives of this study were to elicit self-reported health status, quantify osteoporosis-related burden, and understand preferences for treatment attributes among postmenopausal women with severe osteoporosis in Greece. METHODS: Postmenopausal women with self-reported severe osteoporosis, defined as having suffered at least one osteoporotic fracture and reporting a T-score of ≤−2.5, were asked to evaluate their health status, osteoporosis management, and disease-related physical, emotional, and financial burden. Participants were also asked to rate a series of treatment attributes and state their preference for unlabeled anabolic treatments, based on scenarios describing key treatment characteristics. RESULTS: Approximately one third (31%) of the 186 participants who responded to the survey in full had been living with severe osteoporosis for more than 10 years. Three quarters of participants (72%) considered their overall quality of life (QoL) to be worse than it had been 10 years prior, and the vast majority (89%) attributed this deterioration to osteoporosis. Direct, out of pocket, disease-related costs of at least €100 per month were reported by 86% of participants. Patients attached the greatest value to a treatment that would decrease probability of future fractures, followed by increase in bone density, safety, and mode and frequency of administration. When asked to select their preferred treatment scenario between two anabolic treatments, 70% of participants opted for the scenario that shared treatment characteristics with romosozumab over a scenario that shared treatment characteristics with teriparatide. CONCLUSION: Our study revealed that osteoporosis placed a considerable burden on QoL for postmenopausal women with severe osteoporosis in Greece. Patients reported valuing treatment efficacy, measured through reduction in future fractures and increase in bone density, and safety, as key treatment attributes.
format Online
Article
Text
id pubmed-9840367
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-98403672023-01-15 Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece Souliotis, Kyriakos Golna, Christina Poimenidou, Christina Drakopoulou, Tatiana Tsekoura, Memi Willems, Damon Kountouris, Vasileios Makras, Polyzois Patient Prefer Adherence Original Research OBJECTIVE: The objectives of this study were to elicit self-reported health status, quantify osteoporosis-related burden, and understand preferences for treatment attributes among postmenopausal women with severe osteoporosis in Greece. METHODS: Postmenopausal women with self-reported severe osteoporosis, defined as having suffered at least one osteoporotic fracture and reporting a T-score of ≤−2.5, were asked to evaluate their health status, osteoporosis management, and disease-related physical, emotional, and financial burden. Participants were also asked to rate a series of treatment attributes and state their preference for unlabeled anabolic treatments, based on scenarios describing key treatment characteristics. RESULTS: Approximately one third (31%) of the 186 participants who responded to the survey in full had been living with severe osteoporosis for more than 10 years. Three quarters of participants (72%) considered their overall quality of life (QoL) to be worse than it had been 10 years prior, and the vast majority (89%) attributed this deterioration to osteoporosis. Direct, out of pocket, disease-related costs of at least €100 per month were reported by 86% of participants. Patients attached the greatest value to a treatment that would decrease probability of future fractures, followed by increase in bone density, safety, and mode and frequency of administration. When asked to select their preferred treatment scenario between two anabolic treatments, 70% of participants opted for the scenario that shared treatment characteristics with romosozumab over a scenario that shared treatment characteristics with teriparatide. CONCLUSION: Our study revealed that osteoporosis placed a considerable burden on QoL for postmenopausal women with severe osteoporosis in Greece. Patients reported valuing treatment efficacy, measured through reduction in future fractures and increase in bone density, and safety, as key treatment attributes. Dove 2023-01-10 /pmc/articles/PMC9840367/ /pubmed/36647442 http://dx.doi.org/10.2147/PPA.S385351 Text en © 2023 Souliotis et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Souliotis, Kyriakos
Golna, Christina
Poimenidou, Christina
Drakopoulou, Tatiana
Tsekoura, Memi
Willems, Damon
Kountouris, Vasileios
Makras, Polyzois
Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece
title Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece
title_full Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece
title_fullStr Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece
title_full_unstemmed Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece
title_short Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece
title_sort disease burden and treatment preferences amongst postmenopausal women with severe osteoporosis in greece
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840367/
https://www.ncbi.nlm.nih.gov/pubmed/36647442
http://dx.doi.org/10.2147/PPA.S385351
work_keys_str_mv AT souliotiskyriakos diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece
AT golnachristina diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece
AT poimenidouchristina diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece
AT drakopouloutatiana diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece
AT tsekouramemi diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece
AT willemsdamon diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece
AT kountourisvasileios diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece
AT makraspolyzois diseaseburdenandtreatmentpreferencesamongstpostmenopausalwomenwithsevereosteoporosisingreece